Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None20222021202020192018201720162015201420132012201120102009200820072006 Date Title 1/13/21 Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics 1/8/21 Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference 1/7/21 Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy 12/31/20 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 12/14/20 Sarepta Therapeutics Announces Executive Management Changes 12/7/20 Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 12/4/20 Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy 11/30/20 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/25/20 Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference 11/20/20 Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020 Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page next › Last page last » Displaying 71 - 80 of 730 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None20222021202020192018201720162015201420132012201120102009200820072006 Date Title 1/13/21 Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics 1/8/21 Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference 1/7/21 Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy 12/31/20 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 12/14/20 Sarepta Therapeutics Announces Executive Management Changes 12/7/20 Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 12/4/20 Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy 11/30/20 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/25/20 Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference 11/20/20 Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020 Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page next › Last page last » Displaying 71 - 80 of 730